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Summary
Developing small-molecule antagonists against pro-
tein-protein interactions will provide powerful tools
for mechanistic/functional studies and the discovery
of new antibacterials. We have developed a reverse
yeast three-hybrid approach that allows high-through-
put screening for antagonist peptides against essen-
tial protein-protein interactions. We have applied our
methodology to the essential bacterial helicase-pri-
mase interaction in Bacillus stearothermophilus and
isolated a unique antagonist peptide. This peptide
binds to the primase, thus excluding the helicase and
inhibiting an essential interaction in bacterial DNA
replication. We provide proof of principle that our re-
verse yeast three-hybrid method is a powerful “one-
step” screen tool for direct high-throughput antago-
nist peptide selection against any protein-protein
interaction detectable by traditional yeast two-hybrid
systems. Such peptides will provide useful “leads”
for the development of new antibacterials.
Introduction
Many functions in biology involve large macromolecu-
lar assemblies. The ability of individual protein compo-
nents to interact with each other in a subtle and highly
specific manner often defines mechanistic and regula-
tory aspects of the functional requirements of such as-
semblies. Characterization of the molecular details that
underpin specific protein-protein interactions is a con-
siderable challenge. Traditional structural biology, X-ray
crystallography, nuclear magnetic resonance (NMR)
spectroscopy, and microscopy, provides powerful tools
for studying such interactions, but technological and
experimental limits have made it difficult to apply such
approaches in a generic, high-throughput manner. In-
stead, biochemical techniques, such as phage-display,
yeast two-hybrid (Y2H), and mass spectrometry-based
technologies, have been developed as more generic
methods [1–4]. Such methods have been used extens-
ively to identify protein-protein interaction interfaces,
interacting domains, and small ligands that may medi-
ate such interactions.
The discovery of agonist and/or antagonist peptides*Correspondence: panos.soultanas@nottingham.ac.ukthat regulate protein-protein interactions is of great im-
portance, not only in understanding structural, regula-
tory, and mechanistic aspects of macromolecular as-
semblies, but also in designing new drugs employing
combinatorial and bioinformatics approaches [5, 6].
The use of peptide antagonists to disrupt protein-pro-
tein interactions has been demonstrated in a variety of
systems. Examples include peptides that block IL-1a
binding to type I IL-1 receptor [7], insulin-like growth
factor 1 binding to its regulatory binding protein,
IGFBP-1 [8], the angiogenesis factor VEFGF binding to
its cell surface receptor, KDR [9, 10], IgG Fc binding to
streptococcal protein A [11], and HIV-1 gp120 binding
to CD4 [12]. By comparison, the use of such peptides
against DNA replication is less well documented.
To overcome mechanistic and topological problems
associated with DNA replication, evolution has created
large, complex multiprotein assemblies, like the primo-
some and the replisome. The functions of these assem-
blies are dependent on delicate collaborations of their
component proteins [13–15]. These collaborations are
based upon allosteric protein-protein and protein-DNA
interactions that ensure the effective progression of the
entire assembly through various functional stages in or-
der to complete the effective and faithful replication of
the genetic information. Interference with any of these
essential interactions will inevitably result in stalling of
DNA replication and, ultimately, cell death. Small mole-
cules and/or peptides may act as antagonists to block
such interactions, and may represent a new avenue to
explore and develop new antibacterial drugs. Indeed,
three very recent examples have demonstrated that a
peptide can bind to geminin and suppress DNA replica-
tion in HCT116 colon cancer cells by disrupting the
geminin-Cdt1 interaction [16], whereas a small mole-
cule can mimic the growth-inhibitory effect of phage
polypeptides by disrupting the interaction within a pro-
totypic pair, ORF104 and DnaI (the putative helicase
loader) in Staphylococcus aureus [17] and also other
small molecules can inhibit the interaction of the her-
pes simplex virus DNA polymerase and its processivity
subunit UL42 thus inhibiting viral replication [18].
In this article, we report the discovery, using a reverse
yeast three-hybrid (Y3H) approach, of an antagonist
peptide against the essential interaction between the
main replicative hexameric helicase, DnaB, and the pri-
mase, DnaG, in the Gram-positive Bacillus stearother-
mophilus. This peptide competes with DnaB for binding
to DnaG, thus disrupting an essential bacterial protein-
protein interaction during DNA replication and making
it a powerful “lead compound” for the development of
synthetic peptidomimetics as novel broad-spectrum
antibiotics against bacterial DNA replication. This an-
tagonist peptide will also be useful in studying the mo-
lecular details of the helicase-primase interaction.
Furthermore, although the potential of Y3H in the
analysis of small molecule-protein interactions, as well
as its applications in drug discovery, has been empha-
sized before [19], our data presented here provide proof
of principle that the use of the Y3H technology in a
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ca valuable advance over existing methods. Apart from
being a direct screen for isolating antagonist peptides (
sagainst any protein-protein interaction, it also offers a
unique flexibility, allowing the targeting of either partner u
qof a binary protein complex. It can also be used to in-
vestigate, very rapidly, the effects of mutations on the q
tactivity of the antagonist peptide, and can be easily
adapted as a high-throughput screen in a manner sim- p
ailar to other Y2H high-throughput screens to amplify its
potential as an industrial method for direct antagonist f
rpeptide screening. It offers new opportunities in the
field of peptide-based drug discovery against any pro- i
stein-protein interaction that is detectable by the tradi-
tional Y2H system. D
tResults and Discussion
w
pAntagonist Peptides against the
tHelicase-Primase Interaction
rThe helicase (DnaB)-primase (DnaG) interaction in
oB. stearothermophilus is stable and the complex can
tbe reconstituted and detected from the purified pro-
tteins [20]. A C-terminal domain of DnaG, known as P16,
wcan substitute for the full-length DnaG in the complex
Gand interacts with a linker region that connects the N-
wand C-terminal domains of DnaB to mediate this in-
fteraction both structurally and functionally [21]. How-
mever, the precise structural details of this interaction still
tremain unresolved. The stoichiometry of the complex is
can unresolved issue, with a DnaB6-DnaG3 model being
tthe more likely [20], but with DnaB6-DnaG2 and DnaB6-
pDnaG1 complexes also detectable [21].
fThe interactions of both DnaG and P16 with DnaB
tcan also be detected by traditional Y2H. We devised a
anovel use of the Y3H technology in a reverse manner to
pscreen a commercial MATCHMAKER random peptide
library from Clontech in order to discover antagonist
peptides against this essential bacterial protein-protein A
Cinteraction. Such peptides will provide us with potential
leads for the development of drugs that will target bac- t
aterial DNA replication.
Using the pBridgeBP16 plasmid that carries both t
tGAL4BD-DnaB and GAL4AD-P16 fusions, we pro-
ceeded to test whether we could detect the DnaB-P16 c
Tinteraction. GAL4BD-DnaB is under the control of the
constitutive PADH promoter, whereas GAL4AD-P16 was w
Dplaced under the control of the PMET25 inducible pro-
moter (Figures 1A–1D). In the absence of methionine, (
(the PMET25 promoter is switched on and GAL4AD-P16
is expressed. We found that the DnaB-P16 interaction s
awas detectable in trp−/met− media using the pBridge-
BP16 plasmid (data not shown), indicating that we o
scould now proceed to use the pBridgeBP16 plasmid
in a reverse Y3H experiment to screen for antagonist s
vpeptides using a random peptide library, as shown in
Figure 1E. M
vWe screened approximately 6000 clones from a com-
mercial MATCHMAKER random peptide library from c
Clontech, cloned into the pGADGH plasmid (Figure 1D).
Selection for antagonist peptides was carried out in t
ttrp−/met−/leu− media. Potential clones were isolated for
antagonist functions from the primary Y3H screen and aerified for binding to the primase DnaG (or its P16 heli-
ase-interacting domain) by a secondary Y2H screen
data not shown). One clone was isolated from these
creens and sequenced. It was found to code for a
nique 16-mer peptide that was named lpg1. The se-
uence of lpg1 did not resemble any amino acid se-
uence motifs (or other amino acid sequence parts) of
he DnaB sequence and is presented in Figure 1F. We
roceeded to test its antagonist function, not only
gainst the DnaB-P16 interaction, but also against the
ull-length DnaB-DnaG interaction applying again our
everse Y3H approach, and confirmed that, indeed, it
nhibited this interaction (Figures 2A–2C). Our data
how that lpg1 clearly inhibits the DnaB-DnaG and
naB-P16 interactions in our reverse Y3H system.
The configuration of our reverse Y3H system ensured
hat the GAL4AD-peptide would interact exclusively
ith the GAL4AD-P16 for antagonist activity to be ap-
arent in our screens (Figure 1E). An interaction be-
ween GAL4AD-peptide and GAL4BD-DnaB will simply
esult in β-galactosidase expression. Our system also
ffers the flexibility for selecting antagonist peptides
hat will interact exclusively with the other partner in
he complex. For example, a GAL4BD-peptide fusion
ould result in negative signal only if it interacts with
AL4BD-DnaB, whereas, in this case, an interaction
ith GAL4AD-P16 will result in positive signal. There-
ore, the antagonist activity of the isolated lpg1 peptide
ust be due to specific interactions with P16 (or DnaG)
hat exclude DnaB from the complex. To verify this we
onfirmed the lpg1-DnaG interaction with the conven-
ional Y2H system, using the pASG and pGADGH-lpg1
lasmids in tpr−/leu− media. As expected, lpg1 was
ound to interact with DnaG (Figures 2D and 2E). In con-
rast, lpg1 did not interact with DnaB when tested in
similar manner using the pASB instead of the pASG
lasmid (data not shown).
ntagonist Activity In Vitro
onfirmation of the antagonist activity of lpg1 against
he DnaB-DnaG complex formation was verified by ex-
mining its effect on the DnaG-mediated stimulation of
he ATPase activity of DnaB in vitro. Purified B. stearo-
hermophilus DnaB and DnaG proteins form a stable
omplex that can be isolated by gel filtration [20, 21].
he ATPase activity of DnaB is stimulated significantly
hen in complex with DnaG [20, 21]. However, the
naB-DnaG system is particularly complex, because
1) the stoichiometry of the complex is not absolute and
2) the ATPase kinetic behavior of DnaB is still unre-
olved. Although the majority of the complexes exist in
DnaB6-DnaG3 stoichiometry, a significant percentage
f complexes with DnaB6-DnaG2 and DnaB6-DnaG1
toichiometry also exist [20, 21]. The complexity of this
ystem is amplified further by the ATPase kinetic beha-
ior of DnaB. It does not obey first order Michaelis
enten kinetics [20, 21] and the relative kinetic beha-
ior of the heterogeneous complexes is far from
ertain.
Despite the complexity of this system, we argued
hat if lpg1 reversibly competes with DnaB for binding
o DnaG, the stimulatory effect on the DnaB ATPase
ctivity by DnaG should be inhibited in the presence of
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and Y3H Experiments
(A) Construction of pACT-based plasmids.
The insertion sites of dnaG and p16 genes
are indicated.
(B) Construction of pAS-based plasmids.
The insertion sites for the dnaG and dnaG
genes are indicated.
(C) Construction of pBridge-based plasmids.
The insertion sites for the dnaB and p16
genes are indicated.
(D) The pGADGH plasmid carrying the ran-
dom peptide library at the BamHI-EcoRI, as
indicated. In all cases the direction of the in-
serted genes is indicated by arrows.
(E) Schematic representation of the Y2H sys-
tem with both proteins (P1, P2) on the same
pBridge plasmid (left panel). The plasmid is
selected in trp− media. P1 is expressed con-
stitutively, whereas P2 is expressed only in
met− media. A schematic representation of
the reverse Y3H system is presented in the
right panel. The pGADGH plasmid (carrying
the peptides, P3) is selected in leu− media
and P3 is expressed constitutively. A P2-P3
interaction will give a negative signal,
whereas a P1-P3 interaction will give a posi-
tive signal. Therefore, if P3 interacts with P2
and disrupts the P1-P2 interaction, it can be
detected as a negative signal in the reverse
Y3H system.
(F) The sequence of the lpg1 peptide.lpg1, because lpg1 will bind to DnaG and prevent the
DnaB-DnaG complex formation. Obviously, we cannot
be certain whether all three DnaG molecules need to
be disengaged from the complex or if only one or two
DnaG molecules need to be disengaged before inhibi-
tion of the stimulatory effect can be observed. Indeed
DnaB6-DnaG2 and DnaB6-DnaG1 complexes may still
exhibit stimulated ATPase activity. Despite these com-
plications, we would anticipate that removing all three
DnaG molecules from the complex will lead to inhibition
of the DnaG-mediated stimulatory effect on DnaB
ATPase activity.
We tested this hypothesis employing two different
ATPase assays: a continuous NADH-linked assay that
indirectly measures the rate of ATP hydrolysis by moni-
toring the oxidation of NADH to NAD+ and an end-point
TLC-based assay that directly measures the conversion
of ATP to ADP and inorganic phosphate (Pi). Both as-
says indicated that lpg1 does, indeed, inhibit the DnaG-
mediated stimulation of the DnaB ATPase activity. In
fact, in the TLC-based assay, lpg1 exhibited good in-
hibitory activity from 100- to 3.12-fold molar excess
over DnaG and appeared to lose its inhibitory effect if
diluted further at 1.5-fold molar excess or at half the
concentration of DnaG (Figure 3A). We should empha-size that the TLC-based assay provides a qualitative
rather than an absolute quantitative assay. In fact in this
assay the competitive inhibitory effect of lpg1 is likely
to be magnified. With this assay we are measuring the
percentage of ATP that has been hydrolysed in 10 min.
As ATP is hydrolysed its concentration is reduced with
time thus affecting the complex kinetic behavior of
DnaB. Moreover, since we are not measuring a contin-
uous ATPase rate the lpg1 dose-response in the former
experiment will appear better than the robust end-point
assay. Lpg1 actually reduced the stimulatory effect of
DnaG on the DnaB ATPase activity by 30%–50% as de-
termined by the TLC-based end-point ATPase assay.
Interestingly, a truncated version of lpg1 missing two
amino acid residues ([des-Ser1-Trp2] lpg1) from its N
terminus exhibited significantly reduced antagonist ac-
tivity in the same TLC-based assay compared to the
full length lpg1 (Figure 3B). It inhibited marginally the
stimulatory effect of DnaG by w10% (compare Figures
3A and 3B).
The antagonist effect of lpg1 was also evident in the
continuous NADH-linked assay that measures the
steady-state rate of ATP hydrolysis. This assay mea-
sures real-time continuous rate because the ATP is
continuously regenerated. The ATPase profile of DnaB
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Figure 2. Lpg1 Antagonist Activity in Yeast Hybrid Systems c
lVerification of the antagonist activity of lpg1 against the DnaB-
iDnaG (A) and DnaB-P16 (B) interactions in the Y3H system. In both
Dpanels, positive control experiments for the DnaB-DnaG and DnaB-
DP16 interactions are indicated by the blue coloration, as indicated.
rAdditional controls for the traditional positive interaction between
(the SV40 large T antigen and p53, and the negative control be-
ctween SV40 large T antigen and DnaB, are shown in (C). Verification
rof the lpg1-DnaG interaction by the filter-lift method in a traditional
tY2H system is shown in (D) (yeast patches) and (E) (filter lifts). Lpg1
texhibits clear DnaG binding activity. The positive control indicates
ithe DnaB-DnaG interaction and the negative control indicates no
ainteraction between DnaB and SV40 large T antigen.
tigure 3. Thin-Layer Chromatography-Based ATPase Assays
A) A TLC-based end-point ATPase assay showing the inhibitory
ffect of lpg1 at different concentrations: 100-, 50-, 25-, 12.5-, 6.12-,
.12-, 1.5-, and 0.5-fold molar excess of lpg1 over DnaG as indi-
ated in bars 3–10, respectively. Bars 1 and 2 indicate the ATPase
ctivities of the DnaB-DnaG mixture and the DnaB protein alone,
espectively. Triplicate experiments were carried out, but only one
epresentative TLC plate is shown. The standard deviation is indi-
ated by error bars.
B) The results from a similar assay, but using 100-fold molar ex-
ess of the N-terminally truncated version (des-Ser1Trp2)lpg1 of
pg1 missing the first two N-terminal residues (bar 3). Bar 1 and 2
ndicate the ATPase activities of the DnaB-DnaG mixture and the
naB protein alone, respectively. Bars 4 and 5 indicate controls of
naG and ATP with no protein, respectively. Experiments were car-
ied out in triplicate and error bars indicate the standard deviation.
C) A synopsis of the steady-state ATPase data collected using the
ontinuous NADH-linked ATPase assay. Bar 1 indicates the ATPase
ate of the DnaB (9.2 nM hexamer)-DnaG (55.2 nM monomer) mix-
ure, bar 2 the rate of the DnaB (9.2 nM hexamer) alone, and bar 3
he rate of the DnaB (9.2 nM hexamer)-DnaG (55.2 nM monomer)
n the presence of 5.52 M of lpg1. All reactions were carried out
t 2.0 mM (ATP).iwith this assay in the presence and absence of DnaG
is complicated, with an initial phase that resembles first D
corder kinetics from 0 to 2.0 mM ATP, followed by an
increase between 2.0 and 3.5 mM, and a sharp inhibi- u
ction at higher concentrations of ATP [20, 21, 24]. This
complex kinetic behavior is still unresolved, but has p
sbeen attributed to negative cooperativity of the mono-
mers around the hexameric ring [20]. However, this sug- D
sgestion is still purely speculative and the absolute ki-
netic mechanism behind this complex behavior is still l
ma mystery. Initially, we examined the effect of lpg1 on
the ATPase activity at a fixed 2.0 mM ATP and found o
ethat the ATPase rate of the DnaB-DnaG mixture was
reduced from approximately 15 , s−1 to less than 4 , t
os−1, comparable to the rate for DnaB alone, approxi-
mately 2 , s−1 (Figure 3C). t
uIn order to obtain more reliable quantitative informa-ion for the “dose response” of the lpg1 peptide, we
nvestigated the ATPase profile of the DnaB and DnaB-
naG mixtures in the presence and absence of different
oncentrations of lpg1 at varying concentrations of ATP
p to 2 mM, corresponding to the initial phase of the
omplicated ATPase profile of DnaB (Figure 4). The
resence of DnaG in the reaction mixture in the ab-
ence of lpg1 results in a marked stimulation of the
naB ATPase activity (Figure 4A). Significantly, inclu-
ion of a large excess of the truncated ([des-Ser1-Trp2]
pg1) or mutant ([Ala2]lpg1) peptides resulted only in
arginal differences in the ATPase profile without an
bvious suppression of the DnaG-mediated stimulatory
ffect (Figure 4B). In contrast, the inclusion of lpg1 in
he reaction mixture resulted in a marked suppression
f the DnaG-mediated stimulatory effect, suggesting
hat it inhibits the DnaB-DnaG complex formation (Fig-
re 4C).
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(A) A comparison of the ATPase profile of the DnaB hexamer (9.2
nM) in the presence (closed triangles) and absence (open squares)
of DnaG (55.2 nM) from 0 to 2.0 mM (ATP).
(B) The ATPase profile of the DnaB hexamer (9.2 nM) in the pres-
ence of DnaG (55.2 nM) and 27.6 M of either the truncated lpg1
(open squares) or the mutant lpg1 (closed triangles).
(C) The ATPase profile of the DnaB hexamer (9.2 nM) in the pres-
ence of DnaG (55.2 nM) and varying concentrations of lpg1, 2.76
M (closed circles), 5.52 M (open triangles), 11 M (closed
squares), and 27.6 M (open squares) corresponding to 50, 100,
200, and 500 molar excess of lpg1 over DnaG, respectively. All the
graphs have the same scale axes for direct comparison, and error
bars indicate the standard deviation from duplicate experiments.Because of the complexity of the actual stoichiome-
try of the DnaB-DnaG mixtures and the presence of
heterogeneous complexes with either three, two, or one
DnaG molecule per DnaB hexamer in all our ATPase
assays, we used an excess of DnaG (55.2 nM) over the
DnaB hexamer (9.2 nM), but still cannot ensure abso-
lutely that all the complexes will be of the DnaB6-DnaG3
stoichiometry. Also, any excess of free DnaG is likely to
sequester lpg1 from the solution. The complexity of this
system makes it impossible to engage in the simple
protein-ligand type of analysis for the determination of
a meaningful IC dose response for lpg1.50Figure 5. Sequence Similarities from the Structural Database
The N-terminal half of the lpg1 peptide is homologous to helices
found in the mammalian mevalonate kinase (A) and in the reovirus
RNA polymerase lambda3 (B). In both cases the relevant helices
are indicated in black. The actual sequences and their homology
to the lpg1 sequence are shown in (C).Despite these problems, we carried out a semiquanti-
tative analysis of the lpg1-mediated inhibition, and
established that, under our experimental conditions,
there was no effect observed at 50 molar excess of lpg1
(2.76 M) over the DnaG (55.2 nM) in the reaction mix-
ture, whereas the inhibitory effect gradually increased
as we raised the concentration of lpg1 to 5.52, 11, and
27.6 M, corresponding to 100, 200, and 500 molar ex-
cess of lpg1 over the DnaG in the reaction mixture,
respectively (Figure 4C).
We also verified direct binding of lpg1 to DnaG by
isothermal titration calorimetry (ITC), but the interaction
was very strong and an accurate KB value could not be
calculated (in the Supplemental Data available with this
article online). With tight binding (KB > 109 M−1), ITC
titrations lose their curvature and KB cannot be mea-
sured accurately [25].
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for Antagonist Activity e
In our search for a minimal sequence within lpg1 that 6
might be critical for its antagonist activity, we discov- i
ered that a truncated lpg1 missing the first two N-ter- p
minal serine and tryptophan residues has lost most of D
its antagonist activity. In fact, it suppresses the DnaG- e
stimulatory effect on the DnaB ATPase activity only 6
marginally in both TLC-based (Figure 3B) and NADH- a
linked ATPase assays (Figure 4B). Interestingly, when we i
substituted the tryptophan residue close to the N termi- a
nus for an alanine we found that the mutant ([Ala2]lpg1)
has also lost most of its antagonist activity, with only Lvery weak activity exhibited by this mutant lpg1 in the FNADH-linked assay (Figure 4B). In fact, (Ala2)lpg1 was
Tmarginally worse than the truncated (des-Ser1-Trp2)
clpg1 (compare the two curves in Figure 4B). The fact
bthat both (Ala2)lpg1 and (des-Ser1-Trp2)lpg1 peptides
pexhibit loss of antagonist activity indicates that the an-
ttagonist activity of lpg1 is specific and that the N-ter-
Tminal segment of lpg1 is critical. A subsequent search
sthrough the protein database (PDB) revealed that lpg1
Dhas sequence homology to helices found in the mam-
emalian mevalonate kinase (pdb: 1KVK) and in a viral
opolymerase (pdb: 1MUK) (Figures 5A and 5B) [26, 27].
fInterestingly, in both cases the homology was confined
tto the N-terminal half of the lpg1 peptide (Figure 5C),
pindicating that this region of the lpg1 peptide has the
rpropensity to adopt a helical secondary structure. The
Dhomologous helices in these two proteins do not seem
ato have any functional significance and only in the case
aof the mammalian mevalonate kinase is the homolo-
rgous helix α8 close to a classic four helix bundle, com-
pposed of helices α9 and α10, which constitutes the
bdimerization interface of this protein [26]. Detailed
pstructural analysis will be required to establish whether
flpg1 does indeed adopt a stable secondary structure
iand whether the integrity of this structure is essential
pfor antagonist activity.
i
hLpg1 Inhibits the Stimulatory Effect of DnaG
fon the DnaB Helicase Activity
aHaving established that lpg1 inhibits the stimulatory ef-
(fect of DnaG on the ATPase activity of DnaB, we then
Dexamined the effect on the helicase activity of DnaB.
Using a well-established in vitro helicase assay, we cFigure 6. Effects on the Helicase Activity
DnaG stimulates the helicase activity of
DnaB (A), whereas lpg1 inhibits the stimula-
tory effect of DnaG (B). Lanes 1–6 represent
helicase reaction time points 5, 10, 15, 20,
25, and 30 min, whereas lanes a and b repre-
sent annealed and boiled controls, respec-
tively. The actual gels labeled appropriately
are shown on the left and the quantitative
data are shown as graphs on the right. In (A),
data represent helicase reactions of DnaB in
the presence (circles) and absence (squares)
of DnaG. In (B), data represent helicase reac-
tions of DnaB + lpg1 in the presence (circles)
and absence (squares) of DnaG. Annealed
and displaced oligonucleotide is indicated
with labeled arrows for clarity.howed that lpg1 does indeed inhibit the stimulatory
ffect of DnaG on the helicase activity of DnaB (Figure
). DnaB has a relatively low helicase activity level that
s stimulated significantly by DnaG (Figure 6A). In the
resence of an excess of lpg1, the stimulatory effect of
naG is inhibited significantly, whereas no significant
ffect on the activity of DnaB alone is observed (Figure
B). These data are consistent with our ATPase data
nd, together, provide strong evidence that lpg1 does
ndeed act as an antagonist inhibitor of the DnaG-medi-
ted stimulation of the DnaB activity.
pg1 Disrupts the DnaB-DnaG Complex
ormation In Vitro
he B. stearothermophilus DnaB-DnaG complex, in
ontrast to that of Escherichia coli, is stable enough to
e detected by simply mixing purified DnaB and DnaG
roteins together and then resolving the mixture
hrough a gel filtration column (Figure 7A) [20, 21].
hree DnaG molecules are believed to interact with a
ingle DnaB hexamer, although minor species of
naB6-DnaG2 and DnaB6-DnaG1 complexes may also
xist [20, 21]. We investigated the direct effect of lpg1
n the complex by gel filtration. The complex elutes
rom the column much earlier (10.21 ml elution volume)
han DnaG (13.8 ml elution volume). The resolving
ower of the Superdex S-200 column is insufficient to
esolve clearly the complex (MW, 504 kDa) from the
naB hexamer (303 kDa). We discovered that adding
n excess of lpg1 (175 M) in the DnaB (0.5 M hex-
mer)-DnaG (0.67 M monomer) mixture resulted in the
elease of a substantial amount of DnaG from the com-
lex, confirming that lpg1 competes with DnaB for
inding to DnaG. The antagonist activity of lpg1 is ap-
arent in Figure 7B, with an increase of DnaG eluted
ree from the complex and also a comparative decrease
n the amount of DnaG remaining in the complex (com-
are relative amounts of DnaB and DnaG in the complex
n Figure 7A, lanes 1–3 and Figure 7B, lanes 1–4). Lpg1
as to compete with the DnaB helicase and displace it
rom the preformed DnaB-DnaG complex. Although the
ffinity of lpg1 for DnaG is in the nanomolar region
Supplemental Data), apparently DnaB also binds to
naG with very high affinity, and not all of the DnaB
ould be displaced from DnaG by lpg1. Also, as the
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Primase
Analytical gel filtration experiments of the DnaB (0.5 M hexa-
mers)-DnaG (0.67 M monomers) mixtures in the absence (A) and
presence (B) of lpg1 (175 M). Samples from the peak fractions
were analyzed by SDS-PAGE. The numbers of the lanes in the poly-
acrylamide gels correspond to the numbers of the peak fractions,
as indicated. Lane M shows molecular weight markers, as indi-
cated. lpg1 causes the dissociation of DnaG (67 kDa) from DnaB
(50.5 kDa) in a competitive manner.proteins in the mixture are loaded onto the top of the
column, they begin to separate almost immediately. Be-
cause of its small size, excess lpg1 starts separating
from the rest of the proteins almost immediately. The
remaining DnaB-DnaG complex moves down the col-
umn quicker, and some of the DnaB will remain bound
to DnaG. Thus, only partial, but nevertheless signifi-
cant, displacement of DnaB from the complex by lpg1
is observed.
Our Y3H, Y2H, and in vitro biochemical data for the
lpg1 peptide indicate that it competitively binds to
DnaG and disengages it from the DnaB-DnaG complex.
Because of the complexity of the DnaB-DnaG interac-
tion and the unresolved ATPase kinetics of DnaB, it was
not possible to obtain reliable quantitative information
for the dose response of lpg1 in this system in a manner
analogous to a traditional simple peptide-ligand in-
teraction. However, our combined data provide proof of
principle that the novel use of reverse Y3H technology,
in screening random peptide libraries for antagonistpeptides against protein-protein interactions detecta-
ble by traditional Y2H, is a viable method.
Significance
Overall, our data provide proof of principle and show
that our reverse Y3H approach can directly select an-
tagonist peptides against a protein-protein interac-
tion that is detectable by the traditional Y2H system.
We targeted the bacterial helicase-primase interac-
tion and isolated an antagonist peptide that binds to
the primase and disrupts the helicase-primase com-
plex. Despite the complexity of the DnaB-DnaG sys-
tem, we verified its antagonist activity using a range
of in vitro experiments. We have also shown that both
a truncated and a point mutant version of this peptide
were inactive. Our approach can be adapted to a
rapid, high-throughput direct screening assay for the
isolation of antagonist peptides against either partner
of a binary protein complex, in a similar manner to a
traditional Y2H high-throughput screen [28, 29], and
can be applied to any protein-protein interaction sys-
tem that can be detected by the traditional Y2H
method. It is a significant advance over existing meth-
ods because: (1) it selects antagonist peptides that
bind directly at the protein-protein interaction inter-
face (direct antagonists) or peptides that act allosteri-
cally from a distant binding site (allosteric antago-
nists); (2) it allows the specificity of targeting
exclusively either partner of a binary protein com-
plex; (3) it can be adapted as a high-throughput
method; and (4) once the primary antagonist peptide
has been isolated, it can also be used to rapidly inves-
tigate a large number of mutant antagonist peptides
for improved activity. It will provide a powerful tool for
the development of peptide-based drugs that target
essential protein-protein interactions in a variety of
systems. Isolated antagonist peptides can be used as
“chemical seeds” for further development of chemi-
cal compounds that mimic their antagonist action and
also to probe directly the structural/functional molec-
ular aspects of protein-protein interactions.
Experimental Procedures
Plasmid Constructions for Y2H and Y3H
Our Y2H and 32H methodologies were based upon the MATCH-
MAKER Two-Hybrid system 2 from Clontech. The dnaB, dnaG
genes, as well as the p16 C-terminal fragment of dnaG coding for
a 16 kDa polypeptide (P16) that interacts with DnaB, were all sub-
cloned from their pET expression vectors [20] into the pACT2 and
pAS2-1 vectors, as shown in Figures 1A and 1B.
The dnaB gene was cloned into the NcoI-PstI sites of pAS2-1 to
give pASB (Figure 1B) that codes for the GAL4 DNA binding domain
(BD)-DnaB fusion protein, under the control of the PADH1 constitu-
tive promoter whereas the dnaG and p16 genes were subcloned
into the NcoI-XhoI sites of pACT2 to produce the pACTG and
pACTP16 plasmids, respectively (Figure 1A). Both pACTG and
pACTP16 code for the GAL4 activation domain (AD)-DnaG and AD-
P16 fusion proteins, respectively, both under the control of the
PADH1 promoter. The dnaG gene was also subcloned as an NcoI-
XhoI fragment from the pET21d plasmid [20] into the NcoI-SalI sites
of pAS2-1 (XhoI and SalI sites are compatible), to produce the
pASG plasmid coding for the GAL4BD-DnaG fusion protein under
the control of the PADH1 promoter (Figure 1B).
The dnaB gene was subcloned as NdeI(blunt)-PstI fragment from
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602pASB into the EcoRI(blunt)-PstI sites of pBridge to produce the t
apBridgeB plasmid, coding for a GALBD-DnaB fusion protein and
placing it under the control of the constitutive PADH1 promoter (Fig- a
sure 1C). The p16 gene was subcloned as HindIII(blunt)-HindIII(blunt)
fragment into the NotI(blunt) site of pBridgeB placing the GAL4AD- a
tP16 fusion protein under the control of the inducible PMET25 pro-
moter, to give the pBridgeBP16 plasmid (Figure 1C). The correct t
sorientation was verified by appropriate restriction endonuclease
mapping. The dnaG gene was subcloned as a BglII-BglII fragment m
tfrom pACTG into the same sites of pBridgeBP16, thus replacing
the p16 gene to form the pBridgeBG plasmid, placing the GAL4AD- D
DnaG fusion protein under the control of the PMET25 promoter. Cor-
rect orientation was verified by appropriate restriction endonucle- P
ase mapping. P
The random peptide library was purchased from Clontech and 9
was already cloned into the BamHI-EcoRI sites of pGADGH (Figure 4
1D), under the control of the constitutive PADH1 promoter, with stop v
codons in all three frames immediately after the EcoRI site. The m
library contains 106 independent random peptide clones coding for w
random peptides of 16 amino acids maximum length fused to a
GAL4-AD. 1
N
(Growth Media for Yeast
The AH109 Saccharomyces cerevisiae yeast strain was used in this E
Nstudy. The components of the yeast complete medium (YPD) and
the different synthetic dropout (SD) media, as well as the various c
ssupplements, were purchased from Becton Dickinson and Co. or
Sigma and prepared according to the manufacturer’s instructions. t
DNutritionally selective media were prepared by omitting leucine,
tryptophan, and methionine (or combinations of these) from the
pgrowth media. E. coli XL1-Blue bacteria were cultured in Luria-Ber-
tani (LB) media in the presence of tetracycline. w
e
aYeast Transformations
rYeast cells were made either electrocompetent or chemically-com-
epetent for transformations with DNA. For electrocompetent yeast
wpreparations, cells were cultured first on a YPD plate at 30°C for 3
pdays. Single colonies were used to inoculate liquid YPD cultures
1that were incubated at 30°C overnight with vigorous shaking. Yeast
acells were collected by centrifugation and washed repeatedly in
wfiltered-sterilized, ice-clod 1 M sorbitol. Finally, yeast cells were re-
tsuspended in 200 l of 1 M sorbitol and used for transformation
by electroporation with a MicroPulser (Bio-Rad), according to the
smanufacturer’s instructions.
tFor chemically-competent yeast, single colonies were isolated,
1as described above, and used to inoculate liquid YPD cultures that
swere incubated at 30°C overnight with vigorous shaking. The OD600
1of the cultures were measured and a volume containing approxi-
fmately 2.5 × 108 cells was collected and brought up to 50 ml with
prewarmed YPD and incubated for a further 4 hr at 30°C under
pshaking. Yeast cells were then collected by centrifugation, washed
athree times in double distilled (dd) H2O, resuspended in 1 ml 100
fmM LiOAc, and incubated for 10 min at 30°C. Aliquots of 100 l
iwere used, and from each aliquot, cells were collected by centrifu-
Tgation. The supernatant was removed and 240 l 50 w/v PEG, 36
[l of 1 M LiOAc, 50 l of salmon sperm DNA, 2 l of plamid DNA,
sand 32 l dd H2O were added, in that order. The cells were vortexed
−vigorously and incubated for 30 min at 30°C. They were then heat
shocked at 42°C for 30 min before being collected by centrifuga-
tion. The supernatant was removed and the cells were resus- P
Dpended in 1 ml dd H2O and then loaded onto plates with appropri-
ate SD media. s
AY2H and Y3H Screening
Y2H and Y3H screening were carried out by either the agarose T
eoverlay [22] or filter-lift methods according to the yeast protocols
handbook from Clontech. The pBridgeBP16 plasmid was cotrans-
iformed with a random peptide library cloned into pGADGH plasmid.
Following transformation, double selective plates were incubated 5
rat 30°C for 36 hr. A typical transformation yielded approximately
2000 colonies. An agarose overlay assay was performed, as de- a
oscribed previously [22]. This allowed the rapid identification of po-
tential positive white colonies in which the protein-protein interac- fion appeared to be blocked, thus preventing β-galactosidase
ctivity. Such colonies typically would fail to develop blue color-
tion overnight. These colonies were then patched out on to double
elective plates, cultured for 36 hr at 30°C, and selected again for
bsent β-galactosidase activity. Colonies that exhibited no β-galac-
osidase activity were then cultured and plasmid DNA coding for
he interfering peptide was prepared. As a further control, a yeast
train containing the pASG plasmid was transformed with the plas-
id pGADGH coding for the potentially interfering peptide in order
o confirm the interaction of the peptide with its target protein,
naG.
eptide Synthesis
eptide synthesis was carried out using the standard fluoren-
-ylmethoxycarbonyl (Fmoc) solid-phase approach [23] on a 4-[2#,
#-dimethoxyphenyl(amino)methyl]phenoxyacetamido methyl No-
agel (Rink Amide Novagel, 100–200 mesh, 1% crosslinking, 0.61
mol , g−1) resin. The peptide assembly was achieved in a step-
ise manner, in which amino acid residues were incorporated by
ctivation using N-[(dimethylamino)-1H-1,2,3-triazolo[4,5-b]pyridine-
ylmethylene]-N-methylmethan-aminium hexafluorophosphate
-oxide:7-aza-1-hydroxybenzotriazole:N,N-diisopropylethylamine
HATU:HOAt:DIEA, 1.0:0.5:2.0) in N,N-dimethylformamide (DMF).
xceptionally, the Cys residue was installed by activation using
,N-diisopropylcarbodiimide:HOAt (1:1) in DMF. A 4-fold molar ex-
ess of the activated Fmoc-amino acids was used throughout the
ynthesis and double-couplings (6 hr followed by 18 hr reaction
imes) were typically required. A solution of 20% (v/v) piperidine in
MF was applied for sequential Fmoc-deprotection.
Following solid-phase peptide assembly, the resin-supported
roduct was collected and dried. This material was then treated
ith the mixture trifluoroacetic acid (TFA): H2O:triisopropylsilane:
thyl methyl sulfide (90:5:3:2 v/v, 10 ml) for 4 hr at ambient temper-
ture. The reaction mixture was filtered and the filtrate was evapo-
ated to dryness in vacuo to yield, following trituration with diethyl
ther, the peptide amide as beige solid, which was dissolved in
ater (5 ml) and lyophilized. The desired peptide amide was then
urified by reversed-phase HPLC on a Kromasil C8 column (150 ×
0 mm) at 4.5 ml , min−1. The eluents were: A, 0.06% TFA in water,
nd B, 0.06% TFA in 90% aqueous acetonitrile. The elution profile
as 20%–40% B over a 12 min period, in which the required pep-
ide amide eluted at 9.7 min.
Electrospray-high resolution mass spectrometry (ES-HRMS) analy-
is (Micromass LCT) of the purified peptide showed the presence of
he expected molecular ion (calculated for C78H122N23O19S [MH+],
718.0103; found, 1718.7845). Lpg1 was dissolved as a 10 mg/ml
tock solution in neat DMSO and then brought down to 1 mg/ml in
0% v/v DMSO by the dropwise addition of dH2O. Aliquots were
rozen in liquid N2, stored at −80°C, and used as required.
Both the truncated peptide, (des-Ser1,Trp2)lpg1, and the mutant
eptide, (Ala2)lpg1, were also synthesized and purified using the
pproach outlined above. When analyzed by ES-HRMS, the puri-
ied 14-mer peptide showed the presence of the required molecular
on (calculated MH+, 1443.7158; found, 1443.9214 for [des-Ser1-
rp2]lpg1; and calculated MH+, 1602.8784; found 1602.8606 for
Ala2]lpg1). Both peptides were readily soluble as 1 mg/ml stock
olutions in dH2O. Aliquots were frozen in liquid N2, stored at
80°C, and used as required.
rotein Purifications
naB and DnaG proteins were purified and quantitated as de-
cribed previously [21].
TPase Assays and Analytical Gel Filtration
he DNA-independent ATPase activity of DnaB was assayed using
ither TLC-based or NADH-linked assays.
The end-point TLC-based ATP hydrolysis assay was carried out
n 20 mM Tris (pH 7.5), 50 mM NaCl, 10 mM MgCl2, 2.5 mM EDTA,
mM DTT, 2 mM ATP, 5 pM of 32P-labeled ATP, 0.6 M DnaB (refer-
ing to hexamers), and in the presence or absence of 1.6 M DnaG,
t 37°C for 10 min. Reactions were also carried out in the presence
r absence of lpg1 at various concentrations as indicated in the
igure legends. All reactions were terminated by the addition of 50
Peptides against Bacterial DNA Replication
603mM EDTA and run through TLC plates in 1 M formamide and 0.5
M LiCl for 1 hr. TLC plates were visualized and analyzed using a
phosphorimager. All reactions were carried out in triplicate with
average values plotted.
The continuous NADH-linked ATPase assay was carried out as
described previously for the DnaB-DnaG complex [21] in the pres-
ence or absence of varying concentrations of lpg1 over DnaG. All
reactions were carried out in triplicate and the average values were
plotted. All ATPase rates were defined as molecules of ATP hy-
drolyzed per second per hexamer of DnaB. We should emphasize
here that it is unlikely that all monomers in the hexameric complex
will be hydrolyzing ATP at the same rate. Also, because the stock
lpg1 peptide was dissolved in 10% v/v DMSO, we investigated the
effect of increasing concentrations of DMSO on the ATPase activity
in both assays and found that, up to 50% v/v, there was no detecta-
ble effect on the ATPase activity (data not shown). DnaG does not
exhibit an ATPase activity ([20] and Figure 3B) and synthesizes
primers only in the presence of an appropriate ssDNA substrate
(for a review, see article by Frick and Richardson [30]).
Analytical gel filtration experiments were carried out using a
Superdex S-200 gel filtration column (Amersham Pharmacia Bio-
tech) as described previously [20, 21], using 0.5 M DnaB hexamer,
0.67 M DnaG, and 175 M lpg1. In brief, DnaB and DnaG were
mixed and left for 10 min on ice to enable complex formation, at
which point lpg1 was added, and the mixture of proteins was left
for a further 5 min before being loaded onto the sizing column.
ITC
ITC experiments were carried out with a VP-ITC Microcalorimeter
and data were analyzed with the associated Origin software. Typi-
cally, the appropriate cell was filled with 1.4 ml degassed solution
of DnaG (16.4 M) in 50 mM Tris (pH 7.4), 100 mM NaCl, 10% v/v
DMSO. Samples (5 l) from a 300 l degassed solution of lpg1
(0.45 mM in 10% v/v DMSO) peptide in the same buffer were in-
jected into the DnaG solution at 240 s intervals and data were col-
lected after each injection. A comparative reference control experi-
ment with 10% v/v DMSO was also carried out, and the reference
data were subtracted from the experimental data.
Helicase Assays
Helicase assays were carried out using a well-established in vitro
assay system [20, 21, 24, 31]. A radiolabeled oligonucleotide (5#-GTT
ATTGCATGAAAGCCCGGCTGACTCTAGAGGATCCCCGGGTACGTT
ATTGCATGAAAGCCCGGCTG-3#) was annealed onto ssM13mp18
DNA to produce a 3#- 5#-tailed DNA substrate. One molecule of
DNA substrate is defined as one molecule of ssM13mp18 DNA with
one molecule of oligonucleotide annealed to it. DnaB (25 nM) was
incubated in the helicase reaction mixture (20 mM Tris [pH 7.5], 20
mM MgCl2, 10% v/v glycerol, 5 mM DTT, and 0.5 nM DNA sub-
strate) at 37°C for 5 min in the presence or absence of 150 nM
DnaG and/or 12.5 M lpg1, as appropriate. Reactions were initiated
with the addition of 3 mM ATP and terminated at 5 min intervals by
the addition of helicase stop-buffer (0.4% w/v SDS, 40 mM EDTA,
8% v/v glycerol, 0.1% w/v bromophenol blue). Displaced oligonu-
cleotide was separated from annealed oligonucleotide through a
10% nondenaturing polyacrylamide gel at constant voltage (100 V).
Gels were dried and quantitative analysis was performed using a
phosporimager and associated software (Molecular Imager FX,
Bio-Rad). Helicase activity was defined as a percentage of radiola-
beled oligonucleotide displaced from M13mp18 DNA.
Supplemental Data
Isothermal titration calorimetry data are available at http://
www.chembiol.com/cgi/content/full/12/5/595/DC1/.
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